Adlai Nortye (NASDAQ:ANL) Stock Price Down 5.7%

Adlai Nortye Ltd. (NASDAQ:ANL) shares fell 5.7% on Tuesday . The stock traded as low as $13.60 and last traded at $13.60. 495 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 6,787 shares. The stock had previously closed at $14.42.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a research report on Friday, January 12th.

Adlai Nortye Stock Down 13.2 %

The firm’s 50-day moving average price is $8.95 and its 200-day moving average price is $9.23.

Institutional Investors Weigh In On Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. grew its holdings in shares of Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent SEC filing. Institutional investors and hedge funds own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.